000930308 000__ 03823cam\a2200517Ii\4500
000930308 001__ 930308
000930308 005__ 20230306151448.0
000930308 006__ m\\\\\o\\d\\\\\\\\
000930308 007__ cr\un\nnnunnun
000930308 008__ 200402s2020\\\\sz\\\\\\ob\\\\000\0\eng\d
000930308 019__ $$a1149787235
000930308 020__ $$a9783030388621$$q(electronic book)
000930308 020__ $$a303038862X$$q(electronic book)
000930308 020__ $$z3030388611
000930308 020__ $$z9783030388614
000930308 0247_ $$a10.1007/978-3-030-38862-1$$2doi
000930308 035__ $$aSP(OCoLC)on1147902549
000930308 035__ $$aSP(OCoLC)1147902549$$z(OCoLC)1149787235
000930308 040__ $$aYDX$$beng$$erda$$epn$$cYDX$$dGW5XE$$dEBLCP$$dDKU
000930308 049__ $$aISEA
000930308 050_4 $$aRC268.3
000930308 08204 $$a616.99/4079$$223
000930308 24500 $$aTumor microenvironment /$$cPeter P. Lee, Francesco M. Marincola, editors.
000930308 264_1 $$aCham :$$bSpringer,$$c[2020]
000930308 264_4 $$c©2020
000930308 300__ $$a1 online resource.
000930308 336__ $$atext$$btxt$$2rdacontent
000930308 337__ $$acomputer$$bc$$2rdamedia
000930308 338__ $$aonline resource$$bcr$$2rdacarrier
000930308 347__ $$atext file$$bPDF$$2rda
000930308 4901_ $$aCancer treatment and research ;$$vvolume 180
000930308 504__ $$aIncludes bibliographical references.
000930308 5050_ $$aPreface -- Part I: Imaging of tumor microenvironment, In vivo Imaging -- New technologies to image tumors -- Part II: Immune landscapes and their biology, Systemic correlates of the tumor microenvironment -- Adaptive immunity and the tumor microenvironment -- The biology of immune active cancers and their regulatory mechanisms -- The biology of immune excluded cancers -- Immunoscore -- Part III: The tumor microenvironment and therapy, The Immune Landscape in Women Cancers -- Translational biomarkers, combination therapies and their relationship with immune landscapes -- Effects of radiation on the tumor microenvironment -- Challenges of CAR T cell therapy for solid tumors.
000930308 506__ $$aAccess limited to authorized users.
000930308 520__ $$aThis book addresses the biological processes relevant to the immune phenotypes of cancer and their significance for immune responsiveness, based on the premise that malignant cells manipulate their surroundings through an evolutionary process that is controlled by interactions with innate immune sensors as well as the adaptive recognition of self/non-self. Checkpoint inhibitor therapy is now an accepted new form of cancer treatment. Other immuno-oncology approaches, such as adoptive cell therapy and metabolic inhibitors, have also shown promising results for specific indications. Immune resistance is common, however, limiting the efficacy of immunotherapy in many common cancer types. The reasons for such resistance are diverse and peculiar to the immune landscapes of individual cancers, and to the treatment modality used. Accordingly, approaches to circumvent resistance need to take into account context-specific genetic, biological and environmental factors that may affect the cancer immune cycle, and which can best be understood by studying the target tissue and correlated systemic immune markers. Understanding the major requirements for the evolutionary process governing human cancer growth in the immune-competent host will guide effective therapeutic choices that are tailored to the biology of individual cancers.
000930308 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed April 9, 2020).
000930308 650_0 $$aTumors$$xImmunological aspects.
000930308 650_0 $$aCancer$$xImmunological aspects.
000930308 7001_ $$aLee, Peter P.,$$eeditor.
000930308 7001_ $$aMarincola, Francesco M.,$$eeditor.
000930308 77608 $$iPrint version:$$z3030388611$$z9783030388614$$w(OCoLC)1130665713
000930308 830_0 $$aCancer treatment and research ;$$vv. 180.
000930308 852__ $$bebk
000930308 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-030-38862-1$$zOnline Access$$91397441.1
000930308 909CO $$ooai:library.usi.edu:930308$$pGLOBAL_SET
000930308 980__ $$aEBOOK
000930308 980__ $$aBIB
000930308 982__ $$aEbook
000930308 983__ $$aOnline
000930308 994__ $$a92$$bISE